Xenon Pharmaceuticals Inc. — Director's Dealing 2017

May 16, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Xenon Pharmaceuticals Inc. (XENE)
CIK: 0001582313
Period of Report: 2017-05-12

Reporting Person: ROBIN SHERRINGTON (SVP Bus. & Corp. Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-05-12	Common Shares	M	2057	$3.21	Acquired	6079	Direct
2017-05-12	Common Shares	F	1345	$4.18	Disposed	4734	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-05-12	Stock Option (Right to Buy)	$3.21	M	2057	Disposed	2017-05-18	Common Shares (2057)	Direct

Footnotes

F1: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.

F2: Represents the closing price of the Company's common shares on May 11, 2017, which was converted to a Canadian dollar amount for purposes of net settlement calculations.

F3: The shares subject to the option fully vested on December 31, 2010.